AT-5214 (dexmecamylamine)
Acne Vulgaris (moderate to severe)
Key Facts
About Atacama Therapeutics
Atacama Therapeutics is advancing a targeted oral therapy for Acne Vulgaris, a condition affecting 40-50 million people in the US alone, where current treatments like isotretinoin have significant side effects. The company's lead program, AT-5214, is based on the novel mechanism of inhibiting sympathetic ganglion-mediated sebum production and is currently in a Phase 2 proof-of-concept trial. Founded by veterans from Extera Partners, Atacama seeks to rapidly advance its dermatology portfolio and is actively exploring partnership opportunities for its programs.
View full company profileAbout Atacama Therapeutics
Atacama Therapeutics is advancing a targeted oral therapy for Acne Vulgaris, a condition affecting 40-50 million people in the US alone, where current treatments like isotretinoin have significant side effects. The company's lead program, AT-5214, is based on the novel mechanism of inhibiting sympathetic ganglion-mediated sebum production and is currently in a Phase 2 proof-of-concept trial. Founded by veterans from Extera Partners, Atacama seeks to rapidly advance its dermatology portfolio and is actively exploring partnership opportunities for its programs.
View full company profile